In addition, several studies have revealed the bystander effect of CAR-T therapy in the clearance of antigen-negative tumor cells, which kill tumors based on the secretion of IFN-γ and the Fas/FasL pathway [49, 50]. The gene discussed is IFNG; the disease is neoplasm.